Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 281-290 of 3405 for cancer

Edit search filters
  1. A Study to Evaluate the Effects of Exercise on Fatigue in Thyroid Cancer Survivors

    Rochester, MN

  2. A Study to Evaluate Precision Pharmacogenomics in Cancer Patients

    Scottsdale/Phoenix, AZ

  3. Oncolytic Adenovirus Coding For TNFa And IL2 (TILT-123) With Pembrolizumab Or Pembrolizumab And Pegylated Liposomal Doxorubicin As Treatment For Ovarian Cancer. (PROTA)

    Rochester, MN

  4. A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

    Rochester, MN, Jacksonville, FL

  5. Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

    Rochester, MN

  6. Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

  8. A Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Platinum-Refractory Metastatic Bladder Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

    Rochester, MN

  10. S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

    Rochester, MN

.

Mayo Clinic Footer